Mumps Therapy Pipeline and Viral Partnering Terms and Agreements 2015 Market Research Reports

Sep 18, 2015, 08:30 ET from RnR Market Research

PUNE, India, September 18, 2015 /PRNewswire/ --

Mumps - Pipeline Review, H2 2015 and Viral Partnering Terms and Agreements are the latest 2015 market research reports addition to the infectious disease therapeutics segment of pharmaceuticals business intelligence collection in

Complete report on mumps pipeline review spread across 44 pages, taking about 8 companies, multiple drug profiles and supported with 23 tables and 9 figures is now available at .

This report provides comprehensive information on the therapeutic development for Mumps, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mumps and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage by studying the mumps pipeline review. It strengthens R&D pipelines of mumps by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

This mumps pipeline review research provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. It helps in identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies active in mumps pipeline, identify and understand important and diverse types of therapeutics under development for Mumps as well as plan mergers and acquisitions effectively by identifying key players of the most promising mumps pipeline with the help of this report. The research also helps in planning corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics, developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope as well as modifying the mumps therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from mumps pipeline.

Companies mentioned in this mumps pipeline review report include Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., China National Pharmaceutical Group Corporation, GlaxoSmithKline Plc, Organic Vaccines, Prometheon Pharma, LLC, Sinovac Biotech Ltd. and Zydus Cadila Healthcare Limited. Drug profiles covered in this mumps pipeline research are Cell Therapy for Measles, Mumps and Rubella, measles + mumps + rubella + varicella vaccine, measles + mumps + rubella vaccine, measles [strain schwarz] + mumps [strain RIT 4385] + rubella [strain wistar RA 27/3] vaccine and mumps vaccine. Order a copy of Mumps - Pipeline Review, H2 2015 market research report at .

The second research titled Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the world's leading healthcare companies. Delivery of this report will take 1-3 working days after purchase. Topics like trends in viral partnering deals, average deal terms for headline, upfront and royalty by stage of development, viral partnering agreement structure, viral partnering contract documents, top viral deals by value and most active viral dealmakers are covered in this research study.

The report provides a detailed understanding and analysis of how and why companies enter viral partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors viral technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report contains over 850 links to online copies of actual viral deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In addition, a comprehensive appendix is provided with each report of all viral partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in viral partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of viral technologies and products. Comprehensive table of contents and more on this viral partnering terms and agreements report is available at .

Explore more reports on overall therapeutics market at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

SOURCE RnR Market Research